Latest APC Revisions - April 2019

These outputs are included on the Coventry and Warwickshire netFormulary from March 2019 meeting

DRUG NAME	CATEGORY: Specialist drugs, formulary & non-formulary section									Notes
	SA	SC	SI	SO	Preferred	Second line	Non Formulary	NR	Blacklist	
Semaglutide	Added				Added					**Important** to consider cardiovascular risk - if atherosclerotic CVD is **absent** and a GLP-1 receptor agonist is appropriate
Semaglutide	Added					Added				**Important** to consider cardiovascular risk - if atherosclerotic CVD is **present** and a GLP-1 receptor agonist is appropriate
Roflumilast			Changed to							from **NR**
Independence Easy Access/ Wound Protection/collection Pouch									Added	Code EA1,EA2, VAP1, VAP2
Azithromycin			Added							Prophylaxis of exacerbations in COPD
Levothyroxine (Unlicensed indication)								Added		use in infertility
Liposomal cytarabine- daunorubicin				Added						
Tisagenlecleucel therapy ▼				Added						
Darvadstrocel								Added		
Pembrolizumab with pemetrexed & platinum chemotherapy▼				Added						
Regorafenib				Added						
Axicabtagene ciloleucel therapy▼				Added						
Abemaciclib▼				Added						
Encorafenib with binimetinib ▼				Added						
Sodium valproate										Indication update on Netformulary
Valproic acid										Indication update on Netformulary
Insulin lispro (Insulin lispro Sanofi®)					Added					for new patients only
Ertugliflozin▼	Added									